On  August  31, 2023,  Dr.  B.Partha  Saradhi  Reddy,  Chairman of Hetero Labs Limited，Mr. Bheemireddy Murali Krishnar Reddy, President of Emerging Markets, Mr. Variyath Muraleedharan, VP of International Markets, Mr. Suman Reddy Bandi, Head of API, and Tanya Wang, BD of Formulation， together visited Shenzhen Beimei Pharmaceutical Co., Ltd. Ms. Wu Guangmei, Chairman and CEO of Beimei, Mr. Ren Peng, CTO and Deputy General Manager, Ms. Li Huan, Deputy General Manager and Beimei BD team received them warmly.

(Group photo at the headquarters of Beimei Pharma)

2023 is the fifth year of the in-depth partnership between Beimei Pharma and Hetero , in which the first product approved by both parties in China, Oseltamivir phosphate dry suspension (奥维平®), won the bidding for the eighth batch of the VBP at the highest price in March this year. Hetero visited and exchanged views with Beimei Pharma this time, seeking to cooperate closely with Beimei Pharma in more fields and realize win-win situation.

（Hetero Delegation VisitedBeimei Pharma’s Headquarters）

At the meeting, Ms. Wu Guangmei introduced the history, pipeline, R&D and production of Beimei, and exchanged views on the latest development of cooperative products.

(bilateral seminar)

Ms. Wu Guangmei expressed her gratitude for Hetero's trust and support, and hoped that there would be more cooperation on license-in products in the future. At the same time, Beimei's independently developed and intellectual property products in the field of pediatrics are also looking forward to establishing deeper and closer cooperation with Hetero in the global market.

Dr. B. Partha Saradhi Reddy, Chairman of Hetero, said that Ovipin® is the first product of Hetero approved in China, and Beimei has shown Hetero the prominent and strong strength of Beimei in the product registration landing, marketing, sales performance, collection strategy and brand building, and expressed his heartfelt thanks to Beimei. Hetero hope to establish closer partnership with Beimei in more products and more markets to realize mutual benefits and win-win situation.

Both sides also had in-depth discussions and exchanges on the challenges and opportunities experienced in the course of the enterprise's development, the development of the international market and future market trends.

About Hetero

Founded in 1993, Hetero is India's largest private pharmaceutical company, a leading generic drug manufacturer in India, and one of the world's largest producers of antiretroviral drugs for HIV/AIDS treatment. Committed to the development, production, and marketing of high-quality chemical and biological drugs across various therapeutic areas.

After 30 years of excellence, Hetero has become one of the world's largest producers of ARV APIs & FDFs, with more than 300 APIs and more than 200 FDFs. The company has a network of operations in more than 140 countries and employs more than 22,000 people worldwide. It is globally renowned for its strengths in the development, manufacturing and commercialization of a wide range of products.

About Shenzhen Beimei Pharmaceutical Co., Ltd.

Headquartered in Shenzhen, China, Beimei Pharmaceuticals specializes in pediatric chemical drugs, integrating R&D, global licensing, manufacture, and marketing. With a portfolio covering more than 30 pediatric products, including three innovative drugs with global rights and proprietary intellectual property, we addresses a broad range of areas, such as respiratory, anti-infective (antibacterial), neurology, digestive, endocrine, and otolaryngology.

Beimei has established long-term partnerships with leading pharmaceutical companies including Hetero, Cipla, EMP, Deva, Dr. Reddy's, LTS, MedPharma, Synthon, and NTC. In 2021, Beimei successfully raised over 100 million RMB in Series A and Series B/B+ funding rounds, further accelerating our missions to offer precise dosing, palatable, and high-quality standard products for pediatric patients in China, aiming to pioneer and innovate in the pediatric medication in China.